Epix will resubmit imaging NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryEpix Pharmaceuticals will resubmit an NDA for its novel vascular imaging agent Vasovist (gadofosveset trisodium) in mid-2008. After issuing two "approvable" letters for the agent, FDA proposed a protocol design and statistical analysis plan that could help the drug gain approval. The Lexington, Mass.-based firm said they received an action letter confirming the agreement Feb. 2...
You may also be interested in...
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.